Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study With Expansion to Evaluate the Safety of SEPHB4-HSA in Combination With Cytarabine or Liposomal Vincristine in Patients With Relapsed or Refractory Acute Leukemia

NCT03519984 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT03519984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03519984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study With Expansion to Evaluate the Safety of SEPHB4-HSA in Combination With Cytarabine or Liposomal Vincristine in Patients With Relapsed or Refractory Acute Leukemia
Lead sponsor
University of Southern California
Phase
Phase 1
Overall status
Terminated
Start date
May 9, 2018
Completion date
November 24, 2020
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia arising from previous myelodysplastic syndrome, blasts 5 percent or more of bone marrow nucleated cells, myelodysplastic/myeloproliferative neoplasm, philadelphia chromosome positive, recurrent acute lymphoblastic leukemia, recurrent adult acute myeloid leukemia, refractory acute lymphoblastic leukemia, refractory acute myeloid leukemia, refractory chronic myelogenous leukemia, bcr-abl1 positive, secondary acute myeloid leukemia, t acute lymphoblastic leukemia